Compare BODI & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BODI | TIL |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | United States | United States |
| Employees | 270 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.8M | 74.7M |
| IPO Year | N/A | 2021 |
| Metric | BODI | TIL |
|---|---|---|
| Price | $11.61 | $8.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $15.00 | ★ $125.00 |
| AVG Volume (30 Days) | ★ 71.3K | 19.5K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.48 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.38 | $5.67 |
| 52 Week High | $12.66 | $42.75 |
| Indicator | BODI | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 60.33 | 43.97 |
| Support Level | $9.49 | $6.85 |
| Resistance Level | $12.66 | $9.05 |
| Average True Range (ATR) | 1.13 | 0.45 |
| MACD | 0.03 | -0.06 |
| Stochastic Oscillator | 73.68 | 39.39 |
The Beachbody Co Inc is a fitness and nutrition company providing fitness, nutrition, and stress-reducing programs to its customers. a results-oriented company at the intersection of wellness, technology, and media. The company developed one of the original fitness digital streaming platforms with an extensive library of content containing streaming programs and streaming videos. Company products include Digital Subscriptions, Nutritional Products, and Connected Fitness Products, where the majority of revenue is from Digital Subscriptions. The Company has one operating and reporting segment. Geographically operates in the USA and the rest of the world, with maximum revenue from the United States.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.